Introduction
============

*Escherichia coli* is part of the normal enteric bacterial flora of humans and animals \[[@b1-ophrp-11-216]\]. Nonetheless, some *E. coli* strains have developed pathogenic mechanisms that cause infections in humans and animals \[[@b2-ophrp-11-216]\]. *E. coli* strains can be a source of enteric diarrheagenic infections in human beings \[[@b3-ophrp-11-216]\]. The pathogenicity of *E. coli* is related to the association between many variables, and it is affected by ecological conditions such as microbial species, wellbeing status of the host, association with other microorganisms and antibiotic treatment received \[[@b4-ophrp-11-216]\]. Accordingly, any *E. coli* conveying pathogenicity or antimicrobial resistance (AMR) is possibly pathogenic and harmful to its host \[[@b3-ophrp-11-216]\].

Diarrheagenic *E. coli* (DEC) can be categorized as enteropathogenic *E. coli* (EPEC), enterotoxigenic *E. coli* (ETEC), enteroinvasive *E. coli* (EIEC), enteroaggregative *E. coli* (EAEC) or Shiga toxin producing *E. coli* (STEC) \[[@b5-ophrp-11-216]\]. The categorization of *E. coli* as EPEC is based on the presence of either the *eae* gene (exterior membrane protein adhesion) and/or the *bfpA* gene (plasmid-encoded bundle-forming pilus) \[[@b6-ophrp-11-216]\]. Isolated *E. coli* carrying the *eae* gene is considered as EPEC and the *bfpA* gene further divides EPEC (*eae*+) into typical and atypical \[[@b6-ophrp-11-216]\]. *E. coli* is classified as ETEC based on the presence of *est* and *elt* genes which are heat-stable and heat-labile enterotoxin genes, respectively \[[@b7-ophrp-11-216]\]. The plasmid-encoded genes *CVD432* (a dispersin transporter) and *aaiC* (AggR-activated Island C) are used to classify EAEC *E. coli* isolates \[[@b8-ophrp-11-216]\]. An enteric *E. coli* infection is marked by an immediate evacuation of liquid, non-bloody diarrhea of considerable volume, accompanied by little or no fever \[[@b9-ophrp-11-216]\]. Other common symptoms are abdominal pain, malaise, nausea, and vomiting \[[@b3-ophrp-11-216]\]. Although diarrhoeal disease is usually less harmful to adults than to children, it can reduce the productivity of its workforce which in turn affects the economy of a country. Diarrheal diseases are one of the principal causes of morbidity and mortality all over the world, especially in developing countries \[[@b10-ophrp-11-216]\]. As reported by the Centre for Disease Control and Prevention (CDC) in 2018, diarrheal diseases are the fifth cause of deaths after HIV infection, pneumonia, lung abscess and acute bronchitis in Cameroon \[[@b11-ophrp-11-216]\].

Bacterial diseases are treated with antimicrobial drugs \[[@b12-ophrp-11-216]\]. Overuse of anti-infectious agents is related to the selection of AMR bacterial populations \[[@b13-ophrp-11-216]\]. Several virulent genes and resistant genes, have been identified by PCR that code for the production of efflux pumps proteins, which decrease the permeability of the bacterial membrane, or modifying the substrate targets of antimicrobials have been identified by PCR thereby destroying antibiotic efficacy \[[@b14-ophrp-11-216]\]. The transmission of, and pathways that may lead to, antibiotic resistance and virulence, can be divided into adaptive resistance, innate resistance, and acquired resistance. Physiological changes that lead to elevated mutation rates, i.e. mutation in metabolic genes and regulatory processes, and classic antibiotic inactivation and resistance mechanisms, could be affected by environmental factors \[[@b15-ophrp-11-216]\]. This type of resistance and increased virulence can potentially be shared among bacteria leading to acquired resistance \[[@b15-ophrp-11-216]\]. The rise and spread of bacterial resistance to antibiotics has been recognized as a worldwide burden, particularly in developing countries \[[@b16-ophrp-11-216]\]. Bacterial resistance to antibiotics in the developing countries has been credited to the indiscriminate use of anti-infectious agents in animals bred for food consumption, and overuse, and imperfect prescription of antibiotics (which may influence the recovery of isolates from patients) \[[@b17-ophrp-11-216]\].

The virulence and resistance profiles of enterovirulent *E. coli* strains in adults with enteric infections residing in Cameroon were determined in this study.

Material and Methods
====================

1. Clinical sample and study population
---------------------------------------

Participants in this study were adult patients with enteric diseases, being treated in Mbouda Adlucem hospital and district hospital. These 2 health facilities are reference hospitals in the Bamboutos Division, West Region of Cameroon. Using sterile containers, a total of 599 stool specimens were sampled between May 2016 and May 2018, from patients aged ≤ 20 years. Samples were processed immediately after collection. Sociodemographic information of the study participants was collected using a structured questionnaire. Diarrheal diseases in adults are a common problem diagnosed by physicians in Mbouda. Although a diarrheal disease is usually less harmful to adults than to children, it can affect the economy of a country by reducing the output of its workforce.

2. Isolation and identification of bacteria from stool samples
--------------------------------------------------------------

Each stool sample was diluted 1:4 in sterile distilled water and inoculated onto Mac-Conkey (Becton Dickinson-Difco, Franklin Lakes, NJ, USA) agar plates. The plates were incubated in aerobiosis for 24 hours at 37°C. From morphological examination, colonies that appeared pink, flat, dry and lactose fermenting, with a bordering darker pink area of scurried bile salts were preliminarily reported as *E. coli* and confirmed using motility and biochemical tests such as urease production, indole production, catalase test, citrate utilization, carbohydrate fermentation test and methyl red test \[[@b18-ophrp-11-216]\]. From each sample, 3 distinct colonies were collected for molecular determination of *E. coli* pathotypes (EAEC, EPEC, ETEC, EIEC and STEC) using multiplex and simplex PCR \[[@b19-ophrp-11-216]\].

3. DNA extraction
-----------------

To extract DNA, 3 distinct bacterial colonies were suspended in 200 μL of sterile phosphate buffered saline (1%). The suspension was heated to 100°C for 10 minutes and centrifuged at 10,000 g for 5 minutes. The supernatant fluid containing the DNA was stored at −20°C for supplementary molecular assays.

4. Screening of virulent genes by multiplex and simplex PCR
-----------------------------------------------------------

The detection of 3 types of DEC (EAEC, EPEC and ETEC) was performed using multiplex PCR testing with specific primers ([Table 1](#t1-ophrp-11-216){ref-type="table"}) for the identification of the following virulence markers: EPEC intimin (*eae* gene) exterior membrane protein adhesion, EPEC plasmid-encoded bundle-forming pilus (*bfpA* gene), est and elt for the heat-stable and heat-labile enterotoxin genes of ETEC \[[@b7-ophrp-11-216]\], the EAEC plasmid-encoded gene \[*aatA* or CVD432 (a dispersin transporter)\] and the EAEC chromosomal encoded *aaiC* locus (AggR-Activated Island C). The reaction mixture comprised of 7.4 μL of distilled water, 2.5 μL of 10x PCR buffer with 2 mM of MgCl~2~ (New England Biolab, UK), 0.4 μL of each LT, ST, *bfpA*, *CVD432*, *aaic* primer and 0.44 μL of each *eae* primer, 2 μL of 10 mM of dNTPs \[1.25mM (New England Biolab, UK)\], 0.25 μL of 5.0 U Taq DNA (New England Biolab, UK) and 3.0 μL template DNA. The PCR conditions included initial denaturation at 96°C for 4 minutes, followed by 30 cycles of denaturation at 95°C for 20 seconds, annealing at 57°C for 20 seconds and extension at 72°C for 1 minute, and a final extension at 72°C for 7 minutes. The PCR products were stained after electrophoresis on a 2% agarose gel using an ethidium bromide solution, for 25 minutes, and visualized on a transilluminator. The *E. coli* ATCC 29552 (EAEC), ATCC 35401 (ETEC), ATCC 43893 (EIEC), and ATCC 43895 (EPEC, EHEC, and STEC) were used as positive control strains.

All these genes are virulence determinants for their respective pathogens. Isolates positive for 1 or both of the *eae* and *bfpA* genes were assigned as EPEC. Those positive for either 1 or both EAEC factors (*CVD432*, *aaiC* genes) were designated as EAEC. All *eae*-positive and negative *E. coli* isolates from multiplex PCR were further analyzed by simplex PCR for the *ial* gene (invasive associated protein for EIEC detection), *stx1* (shiga toxins 1) and *stx2* (shiga toxins 2) virulent genes \[[@b6-ophrp-11-216]--[@b8-ophrp-11-216]\]. Isolates positive for the *ial* gene were assigned as EIEC, and those positive for 1 or both of the *stx1*, *stx2* genes were considered as STEC.

5. Simplex PCR for ial gene detection
-------------------------------------

The simplex PCR reaction mixture for EIEC detection contained 15.5 μL of distilled water, 2.5 μL of 10x PCR buffer with 2 mM of MgCl~2~ (New England Biolab, UK), 1.0 μL of each *ial* primer ([Table 1](#t1-ophrp-11-216){ref-type="table"}), 2.0 μL of 10 mM of dNTPs \[1.25mM (New England Biolab, UK)\], 0.20 μL of 5.0 U Taq DNA (New England Biolab, UK) and 3.0 μL template DNA. The PCR conditions consisted of an initial denaturation at 94°C for 5 minutes, followed by 30 cycles of denaturation, annealing and extension at 94°C for 30 seconds, 60°C for 30 seconds, and 72°C for 1 minute, respectively, and a final extension at 72°C for 7 minutes. Positive control strains were included in each batch of tests. The PCR products were stained after electrophoresis on a 2% agarose gel using an ethidium bromide solution, for 25 minutes, and visualized on a transilluminator.

6. Simplex PCR for stx1 (shiga toxins 1) and stx2 (shiga toxins 2) genes detection
----------------------------------------------------------------------------------

The simplex reaction mixture comprised of 13.25 μL distilled water, 2.5 μL of 10x PCR buffer with 2 mM of MgCl~2~ (New England Biolab, UK), 2.0 μL of each *shiga toxin* primer ([Table 1](#t1-ophrp-11-216){ref-type="table"} \[[@b19-ophrp-11-216]--[@b21-ophrp-11-216]\]), 2 μL of 10 mM of dNTPs \[1.25mM (New England Biolab, UK)\], 0.25 μL of 5.0 U Taq DNA (New England Biolab, UK) and 3.0 μL template DNA. The PCR conditions involved an initial denaturation at 94°C for 5 minutes, followed by 30 cycles of denaturation at 94°C for 90 seconds, annealing at 55°C for 90 seconds, an extension at 72°C for 90 seconds, and a final extension at 72°C for 7 minutes.

7. Antimicrobial susceptibility testing
---------------------------------------

All isolates possessing at least 1 virulence gene as determined by multiplex and simplex PCR were subjected to antibiotic susceptibility testing using the Kirby Bauer disk diffusion method \[[@b22-ophrp-11-216]\] for the following antimicrobials: ampicillin (AMP, 10μg), azithromycin (AZM, 15μg), cefotaxime (CTX, 30 μg), ceftazidime (CAZ, 30μg), ceftriaxone (CRO, 30μg), chloramphenicol (CHL, 30μg), ciprofloxacin (CIP, 5 μg), gentamicin (GEN, 10 μg), meropenem (MEM, 10μg), nalidixic acid (NA, 30 μg), norfloxacin (NOR, 10 μg), ofloxacin (OFX, 5 μg), tetracycline (TET, 5μg), and trimethoprim-sulphamethoxazole (SXT, 23.75/1.25 μg) \[Becton Dickinson and Company, Sparks, MD 21152 USA\]. *E. coli ATCC 25922* was used as a quality control strain. The expression of the results as sensitive, intermediate and resistant was performed according to Clinical and Laboratory Standards Institute guidelines \[[@b23-ophrp-11-216]\]. Multi drug resistance (MDR) was considered as bacterial resistance to 3 antibiotics belonging to at least 3 classes or families \[[@b24-ophrp-11-216]\].

8. Screening of antibiotic resistant genes
------------------------------------------

Simplex PCR was utilized for the determination of resistant genes: β-lactamases *blaTEM*, *blaOxa* and *blaPSE- 1*, chloramphenicol acetyltransferase (*cat1* and *cat2*), non-enzymatic or plasmid chloramphenicol resistance (*cmIA*) and chloramphenicol efflux pump *floR* (plasmid or chromosome-encoded chloramphenicol exporter), tetracycline efflux pumps *tetA*, *tetB* and *tetG*, and dihydropteroate synthases *sul1*, *sul2* and *sul3* and dihydofolate reductase *dfrA1*, *dfrA7* and *dfrA12* \[[@b25-ophrp-11-216]\]. For these antibiotic resistant genes, the PCR reaction mixture contained 8.5 μL of distilled water, 1.5 μL of 10x PCR buffer with 2 mM of MgCl~2~ (New England Biolab, UK), 0.15 μL of each primer, 1.5 μL dNTPs \[1.25mM (New England Biolab, UK)\], 0.20 μL of 5.0 U Taq DNA (New England Biolab, UK) and 3.0 μL template DNA. [Table 2](#t2-ophrp-11-216){ref-type="table"} shows the specific primer sequences and PCR conditions \[[@b26-ophrp-11-216]--[@b36-ophrp-11-216]\].

9. Screening of mutations in the DNA gyrase (gyrA, gyrB) and topoisomerase (parC) genes
---------------------------------------------------------------------------------------

The mutations in chromosomal DNA gyrase (*gyrA*, *gyrB*) and DNA topoisomerase (*parC*) carrying the quinolone resistance-determining regions were investigated using simplex PCR followed by sequencing \[[@b37-ophrp-11-216],[@b38-ophrp-11-216]\]. For each of the *gyrA*, *gyrB* and *parC* genes, the PCR reaction mixture contained 8.5 μL of distilled water, 1.5 μL of 10x PCR buffer with 2 mM of MgCl~2~ (New England Biolab, UK), 0.15 μL of each primer, 1.5 μL dNTPs \[2.5mM (New England Biolab, UK)\], 0.20 μL of 5.0 U Taq DNA (New England Biolab, UK) and 3.0 μL template DNA. The PCR conditions and amplicon sizes are shown in [Table 2](#t2-ophrp-11-216){ref-type="table"}. Amplified DNA products were resolved by electrophoresis on 2% agarose gels and stained with ethidium bromide. PCR products were purified for sequencing by BigDye XTerminator purification method (Foster City, USA). The forward and reverse strands were sequenced in Applied Biosystems Genetic Analyzers 3130/xl (Applied Biosystems) with the same PCR primer sets. Raw sequences of each *gyrA*, *gyrB* and *parC* genes were reviewed by visual inspection using Sequence Scanner software v2.0 (64-bit, \[Applied Biosystems genetic analyzer instruments\]), studied with the BLAST and FASTA programs of the National Centre of Biotechnology Information ([www.ncbi.nlm.nhi.gov](www.ncbi.nlm.nhi.gov)) and compared with the *gyrA*, *gyrB* and *parC* reference sequences of *E. coli* str. K-12 substrain MG1655 in the GenBank database.

10. Ethical considerations
--------------------------

Ethical endorsement was acquired from the Cameroon National Ethics Committee, Ministry of Public Health (2018/06/1054/CE/CNERSH). Before data collection, authorizations were obtained from each director of Mbouda, Adlucem and district hospitals. Information sheets presenting the objective and procedures of the study were explained to each participant. Answers were also given to their questions concerning the study. Written informed consent was obtained from each participant before his/her discretionary participation.

11. Statistical analysis
------------------------

Epi Info version 7.2.2.6 (CDC, Atlanta, USA) was used for the statistical analysis. Frequencies and percentages were computed, and the study variables were compared using 2-tailed Chi-square test and correlation analysis. Results were considered significant if *p* \< 0.05.

Results
=======

1. Distribution of DEC pathotypes and virulent genes among total enterovirulent E. coli (n = 119)
-------------------------------------------------------------------------------------------------

Based on macroscopic colony characteristics (pink, flat, dry and lactose fermenting colonies with a bordering darker pink area of scurried bile salts) and biochemical tests, a total of 377 *E. coli* isolates were obtained from 599 stool samples. Multiplex and simplex PCR used to target virulent genes enabled the identification of 119 enterovirulent *E. coli* isolates among which 56 (47.05%) were atypical EPEC (*eae* gene only), 44 (36.97%) were EAEC, 12 (10.08%) belonged to STEC, and 7 (5.88) were EIEC. None of the stool specimens was positive for typical EPEC (both *eae* and *bfpA*) and ETEC. The occurrence of DEC among females (52.94%) was slightly higher than in males (47.06%). The participant's average age was 43.42 ± 15.61 years (ranging from 20 to 88 years) for participants in which 119 enterovirulent *E. coli* were detected. DEC was most prevalent in the age group 40 \< 50 years (30.25%), with a predominance of EPEC (18.49%) compared with EAEC (7.56%), EIEC (2.52%) and STEC (1.68%). Vomiting and diarrhea, and fever and diarrhea, were observed in 21.85% and 15.13% of patients affected with EPEC, respectively. Patients infected with EAEC (20.17%), EIEC (3.36%) and with STEC (7.56) had abdominal cramps, dysenteric stools/stomach cramps and diarrhea, respectively ([Table 3](#t3-ophrp-11-216){ref-type="table"}).

The molecular detection of virulence associated genes ([Figure 1](#f1-ophrp-11-216){ref-type="fig"}) showed the presence of the *eae* gene was predominant in 47.06% of the total isolated DEC strains, followed by the *CVD432* gene (33.61%), *aaic* (13.45%), *stx2* (10.08%) and *stx1* (0.84%). The presence of associations *CVD432/aaic* and *stx1/stx2* genes was observed in 10.08% and 0.84%, respectively, whilst the genes *bfpA*, and *eae/bfpA* were absent.

2. AMR profile of enterovirulent E. coli isolates
-------------------------------------------------

The antibiotic resistance patterns of *E. coli* isolates are summarized in [Table 4](#t4-ophrp-11-216){ref-type="table"}. The *E. coli* isolates exhibited high resistance to antibiotics such as ampicillin (94.64% EPEC, 91.67% STEC, 59.09% EAEC, and 57.14% EIEC; X^2^ = 21.94, *p* = 0.001) and sulfamethoxazole-trimethoprim (100% EPEC and 83.33% STEC, 81.82% EAEC and 71.43% EIEC; X^2^ = 12.67, *p* = 0.005). EPEC (92.86%), STEC (83.33%), EAEC (75.00%) and EIEC (13.64) showed resistance against tetracycline although these results were not statistically significant. *E. coli* isolates showed significant susceptibility to the following antibiotics: ceftazidime, chloramphenicol, ciprofloxacin, gentamicin and norfloxacin. All isolates were 100% susceptible to meropenem.

3. Distribution of the antimicrobial resistant genes according to the pathotype groups
--------------------------------------------------------------------------------------

Molecular identification of resistant genes using PCR ([Table 5](#t5-ophrp-11-216){ref-type="table"}) disclosed the existence of broad spectrum beta lactamase (BSBL) genes *blaTEM* (52.10%), *blaOxa* (9.24%) and *blaPSE-1* (0.84%). The occurrence of each resistant gene was compared with the resistance profile of enterovirulent *E. coli* against the antibiotics. The results showed the *blaTEM* gene was significantly higher (*p* = 0.001) in ampicillin resistant STEC (75.00%), followed by EPEC (66.07%), EAEC (31.82%) and EIEC (28.57%), whilst blaOxa was significantly higher (*p* \< 0.001) in ampicillin resistant EIEC (28.57%) compared with ampicillin resistant EAEC (20.45%), EPEC (0%) and STEC (0%). The distribution of chloramphenicol resistance genes was 10.08% for both *cat1* and *cat2*, and 0% for both *cmlA* and *floR*. *cat1* and *cat2* genes were significantly higher in chloramphenicol resistant EIEC compared with other chloramphenicol resistant DEC (*p* \< 0.001). Tetracycline resistant genes *tetB*, *tetA* and *tetG*, were detected in 64.71%, 59.94% and 17.65% of the total tetracycline resistant isolates, respectively. *tetB* was significantly higher in tetracycline resistant STEC (*p* = 0.006) whilst *tetG* was higher in EIEC (*p* \< 0.001) compared with other tetracycline resistant DEC. Sulfonamide resistant genes *sul1*, *sul2* and *sul3* were identified in 16.81%, 71.43% and 5.88% of sulfonamide resistant isolates, respectively, and trimethoprim resistant genes *dfr1A*, *dfrA7* and *dfrA12* were present in 6.72%, 0%, and 0.84% of trimethoprim resistant isolates, respectively. *sul2* was significantly higher in STEC whilst *sul1* was higher in EAEC compared with other *E. coli* pathotypes (*p* \< 0.05).

4. Presence of amino acid mutation in quinolone resistance-determining regions
------------------------------------------------------------------------------

The mutations in the chromosomal DNA gyrase (*gyrA*, *gyrB*) and DNA topoisomerase (*parC*) carrying the quinolone resistance-determining regions were investigated using simplex PCR followed by sequencing. Six quinolone resistant *E. coli* and 4 sensitive strains were sequenced. No mutation was observed in the *gyrA*, *gyrB* and *parC* protein sequences of all sensitive isolates. For the quinolone resistant *E. coli*, no mutation was observed in the *gyrB* protein sequence of all analyzed isolates. Alignment of the *gyrA* (DNA *GyrAse*) and *parC* (DNA topoisomerase) protein sequence of 1 quinolone resistant *E. coli* isolate is shown in [Figures 2](#f2-ophrp-11-216){ref-type="fig"} and [3](#f3-ophrp-11-216){ref-type="fig"}. A double mutation was observed in *gyrA* (accession number: MT334396) at position 83 \[S83L (bestows high-level resistance)\] and position 87 \[D87N (bestows low-level resistance)\] for a single isolate resistance to OFX, NOR, CIP and NA, whilst a single mutation in *parC* (accession no.: MT334398) was seen at position 80 (S80I) in the same isolate. There were 33.33% (*n* = 2) of *E. coli* isolates resistant to NA and susceptible to OFX, NOR and CIP presented a single mutation in *gyrA* (accession no.: MT334397) at position 83 (S83L).

5. Associations between E. coli virulent genes and antibiotics susceptibility phenotypes
----------------------------------------------------------------------------------------

Significant associations between *E. coli* virulent genes and antibiotic sensitivity phenotypes were observed. Resistance to chloramphenicol was positively associated with *aaic* and *CVD432* (*p* \< 0.05), and negatively associated with *eae* (*p* \< 0.05). Resistance to gentamicin was marked by its positive association with *CVD432* and negative association with *eae* and *aaic* (*p* \< 0.05; [Table 6](#t6-ophrp-11-216){ref-type="table"}).

6. Associations between virulent and antibiotic resistance genes
----------------------------------------------------------------

There were significant associations between virulent genes and antibiotic resistance genes. Enterovirulent *E. coli* carrying *blaOxa*, *blaTEM*, *cat1*, *cat2*, *sul1*, and *sul2* genes were distinguished by their associations. Each of the 3 virulent genes (*eae*, *aaic*, *CVD432*), and the *cat1* and *cat2* gene, were each positively associated to *aaic* and *CVD432* gene (*p* \< 0.05), and negatively associated to the *eae* gene (*p* \< 0.05; [Table 7](#t7-ophrp-11-216){ref-type="table"}). Concerning chloramphenicol resistance, the associations obtained genetically are in agreement with those obtained phenotypically to virulent genes.

7. Multi-drugs resistant profile
--------------------------------

The features of the *E. coli* pathotypes according to MDR status are presented in [Figure 4](#f4-ophrp-11-216){ref-type="fig"}. EPEC and EAEC were more likely (*p* \< 0.05) to be MDR (89.29%, 54.55%) than non-MDR (10.71%, 45.45%), respectively.

Discussion
==========

The diversity, as well as the pathogenicity of the *E. coli* strains are due to the insertion of genetic material, whether in the form of transposon, bacteriophage or plasmid \[[@b39-ophrp-11-216]\]. This incorporated genetic material may contain genes involved in virulence and resistance against antimicrobial drugs \[[@b40-ophrp-11-216]\]. Enterovirulent *E. coli* has been identified as a major cause of diarrhea in developing countries \[[@b41-ophrp-11-216]\]. These pathogens are not routinely sought in developing countries due to deficiency of infrastructures such as advanced molecular techniques. Consequently, the precise burden of enterovirulent *E. coli* among adult patients throughout Cameroon, notably the Bamboutos Division, is uncertain.

In the present study, stool samples were collected from patients with enteric diseases, being treated in Mbouda, Adlucem and district hospitals, in the Bamboutos Division, West region of Cameroon. This is the first in-depth study of enterovirulent *E. coli* in the population of Mbouda. The occurrence of atypical EPEC was higher compared with EAEC, STEC and EIEC. None of the stool specimens were positive for typical EPEC (both *eae* and *bfpA*) and ETEC. Similar results obtained in Mangalore, India showed that, the most prevalent DEC was atypical EPEC, followed by EAEC and STEC \[[@b42-ophrp-11-216]\], contrary to that of Spano, Brazil \[[@b43-ophrp-11-216]\].

The occurrence of EPEC was higher in patients with symptoms of vomiting and diarrhea, and fever and diarrhea, while patients infected with EAEC, EIEC and STEC reported abdominal cramps, dysenteric stools/stomach cramps and diarrhea, respectively. It has been shown that, various *E. coli* pathotypes contribute to diarrheal episodes by inhibiting the serotonin transporter, although the mechanism is poorly understood \[[@b6-ophrp-11-216]\]. Among all enterovirulent *E. coli*, EPEC was observed to be the most widespread pathotype for diarrheal infection in Mbouda.

The molecular detection of virulent associated genes revealed that, the occurrence of the *eae* gene in total screened isolates was high compared with *CVD432*, *aaic*, *stx1* and *stx2*. The association of the *CVD432/aaic* and *stx1/stx2* genes was observed in 10.08% and 0.84%, respectively, whilst the other genes (*bfpA*, *eae/bfpA*) were absent. These findings are comparable to those obtained in a study reported in India \[[@b42-ophrp-11-216]\]. The distribution of *E. coli* pathotypes and virulent genes depends on geographical and socio-economic features of each region. In Tehran, Shahrokhi et al showed that, *ST* was the most frequent toxin type followed by *LT* and *LT/ST* \[[@b44-ophrp-11-216]\]. Dominance of the *ST*-expressing ETEC has been documented in Egypt, Bangladesh, and Iran \[[@b44-ophrp-11-216],[@b45-ophrp-11-216]\].

Highly significant resistance rates were observed for ampicillin and sulfamethoxazole-trimethoprim in this study. EPEC (92.86%), STEC (83.33%), EAEC (75.00%) and EIEC (13.64) showed non-significant resistance to tetracycline. These results are comparable to the global general trend of fecal *E. coli* isolates \[[@b3-ophrp-11-216]\]. Nevertheless, resistance rates fluctuate by country. In comparison, the rates observed in this study for Cameroon are higher than those registered in 6 European countries including Russia \[[@b46-ophrp-11-216]\], and lower than those from Nigeria \[[@b47-ophrp-11-216]\]. The spectrum of antibiotics used in Cameroon for prophylaxis, therapy, growth promotion and auto-medication can directly affect AMR of endogenous bacteria. In addition, the environment can also be a source for resistant microorganisms and resistant genes for humans \[[@b48-ophrp-11-216]\].

BSBL genes *blaTEM* and *blaOxa*, were detected in a wide number of isolates, contrary to an existing report \[[@b49-ophrp-11-216]\]. This may have been the cause of resistance to ampicillin in the study isolates. The prevalence of chloramphenicol resistant genes *cat1* and *cat2*, was higher in *E. coli* isolates resistant to chloramphenicol compared with the *cmlA* and *floR* genes. This indicates non-enzymatic or plasmid chloramphenicol resistant mechanisms of study isolates \[[@b50-ophrp-11-216]\]. Tetracycline genes *tetB*, *tetA*, and *tetG*, were detected in 64.71%, 59.94% and 17.65% of the total tetracycline resistant isolates, respectively, with a predominance among tetracycline resistant STEC for *tetB* and EIEC for *tetG*. These results show that, study isolates express resistance via an efflux mechanism \[[@b51-ophrp-11-216]\]. *sul1*, *sul2* and *sul3* (dihydropteroate synthase genes) genes were detected in 16.81%, 71.43% and 5.88% of trimethoprim-sulphamethoxazole resistant isolates, respectively. These genes play a major role in sulfonamide resistance and are remarkably related to integrons and transposons. High occurrence of the *sul2* gene observed in this study is in accordance with the results obtained by Wu et al in 2010 \[[@b52-ophrp-11-216]\]. The genes *dfr1A*, *dfrA7* and *dfrA12* were detected in 6.72%, 0.00%, and 0.84% of trimethoprim resistant isolates, respectively, *dfr1A* was the most commonly identified. The occurrence of antibiotic resistance fluctuates with respect to each country. These findings are similar to those from a report in Iran \[[@b53-ophrp-11-216]\].

A double substitution (S83L; D87N) was seen in the *gyrA* protein sequence for a single isolate resistant to OFX, NOR, CIP and NA whilst a single mutation in *parC* was seen at position 80 (S80I). 33.33% *E. coli* isolates resistant to NA and susceptible to OFX, NOR and CIP presented a single mutation in *gyrA* at position 83 (S83L). Many factors such as animal-to-human transfer of resistant bacteria have been reported to be the main contributor to the appearance of highly quinolone-resistant bacteria, mainly due to mutations in the DNA gyrase and topoisomerase IV genes \[[@b54-ophrp-11-216]\].

Many associations between virulent factors and AMR were identified. The most remarkable was chloramphenicol resistance that was positively associated with *aaic* and *CVD432*, and negatively associated with *eae*, and that of gentamicin which was distinguished by its positive association with *CVD432* and negative association with *eae* and *aaic*. The combination of *E. coli* virulent factors and antibiotic resistance has been reported although the molecular pathways underlying the association between resistance and virulence is not clearly understood.

Other associations were observed between virulent genes and antimicrobial resistant genes. Enterovirulent *E. coli* carrying the *blaOxa*, *blaTEM*, *cat1*, *cat2*, *sul1*, and *sul2* genes, were distinguished by their association with each of the 3 virulent genes (*eae*, *aaic*, *CVD432*). *cat1* and *cat2* genes were each positively associated with *aaic* and the *CVD432* genes, and negatively associated with the *eae* gene. Concerning chloramphenicol resistance, the associations obtained genetically are in agreement with those obtained phenotypically to virulent genes.

These findings are of huge public health prominence since the virulent and resistant genes of enterovirulent *E. coli* are not routinely assessed in hospital-based laboratories in Mbouda, Cameroon. However, the study population in this present study was limited to patients aged ≥ 20 years. In addition, the focus of this work was on enterovirulent *E. coli* isolates. Even though non-enterovirulent *E. coli* isolates were obtained, no further molecular studies were performed. Enterovirulent *E. coli* is reputed to carry resistant genes on plasmids, transposons, and integrons. These mobile genetic materials can be transferred between microorganisms of the same species or different genera across horizontal gene transfer \[[@b40-ophrp-11-216]\]. Thus, additional studies are needed to evaluate the risks associated with *E. coli* which carry antibiotic resistance genes, and the capability of transferring these genes to other bacteria, including commensal *E. coli* and other enteric bacterial pathogens which could have a prejudicial effect on public health.

Conclusion
==========

This study, the first in Mbouda, Cameroon to determine the virulence and antibiotic resistance of enterovirulent *E. coli* isolates from a sample of the Mbouda adult population with enteric diseases. The presence of atypical EPEC, EAEC, STEC, and EIEC was observed. A high antibiotic resistance phenotype was noted, with resistance to commonly used antibiotics including ampicillin, sulfamethoxazole-trimethoprim, and tetracycline. Significant susceptibility to antibiotics such as ceftazidime, chloramphenicol, ciprofloxacin, gentamicin, norfloxacin and meropenem, was equally observed. BSBL genes blaTEM and blaOxa, chloramphenicol resistant genes (*cat1* and *cat2*), tetracycline resistant genes (*tetB*, *tetA* and *tetG*), dihydropteroate synthase genes (*sul1*, *sul2* and *sul3*) and trimethoprim resistant genes (*dfr1A*, *dfrA7* and *dfrA12*) were detected in the respective antibiotic resistant enterovirulent *E. coli*. Many associations between virulent factors and antimicrobial resistant phenotype, and between virulent genes and antimicrobial resistant genes, were noted. The detection of virulent and highly antibiotic resistant genes in fecal *E. coli* in Mbouda adults suggested that measures should be taken to reduce the potential harm to public health, such as the appropriate etiological diagnosis and reasonable use of antimicrobial agents.
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###### 

Specific PCR primers used in this study for determination of the virulent genes.

  Target gene   Primers                     Primer sequences            Amplicon sizes   References
  ------------- --------------------------- --------------------------- ---------------- -------------------------
  *elt/ETEC*    LT-F                        CACACGGAGCTCCTCAGTC         508 bp           \[[@b19-ophrp-11-216]\]
  LT-R          CCCCCAGCCTAGCTTAGTTT                                                     
                                                                                         
  *est*/ETEC    ST-F                        GCTAAACCAGTAGAGGTCTTCAAAA   147 bp           \[[@b19-ophrp-11-216]\]
  ST-R          CCCGGTACAGAGCAGGATTACAACA                                                
                                                                                         
  *bfpA*/EPEC   BFPA-F                      GGAAGTCAAATTCATGGGGG        367 bp           \[[@b19-ophrp-11-216]\]
  BFPA-R        GGAATCAGACGCAGACTGGT                                                     
                                                                                         
  *eae*/EPEC    EAE-F                       CCCGAATTCGGCACAAGCATAAGC    881 bp           \[[@b19-ophrp-11-216]\]
  EAE-R         CCCGGATCCGTCTCGCCAGTATTCG                                                
                                                                                         
  *aatA*/EAEC   CVD432-F                    CTGGCGAAAGACTGTATCAT        630 bp           \[[@b19-ophrp-11-216]\]
  CVD432-R      CAATGTATAGAAATCCGCTGTT                                                   
                                                                                         
  *aaic*/EAEC   AAIC-F                      ATTGTCCTCAGGCATTTCAC        215 bp           \[[@b19-ophrp-11-216]\]
  AAIC-R        ACGACACCCCTGATAAACAA                                                     
                                                                                         
  *stx1*/STEC   EVT1                        CAACACTGGATGATCTCAG         349 bp           \[[@b20-ophrp-11-216]\]
  EVT2          CCCCCTCAACTGCTAATA                                                       
                                                                                         
  *stx2*/STEC   EVS1                        TACAGTCGTCACTCACTGGT        110 bp           \[[@b20-ophrp-11-216]\]
  EVC2          CTGCTGTCACAGTGACAAA                                                      
                                                                                         
  *ial*/EIEC    ial-F                       CTGGATGGTATGGTGAGG          700 bp           \[[@b21-ophrp-11-216]\]
  ial-R         GGAGGCCAATTATTTCC                                                        

EAEC = enteroaggregative *E. coli*; EIEC = enteroinvasive *E. coli*; EPEC = enteropathogenic *E. coli*, ETEC = enterotoxigenic *E. coli*.

###### 

Specific PCR primers used in this study for the determination of antibiotics resistance genes.

  Antibiotics                      Target gene                   Primers                      Primer sequences              Amplicon sizes   Annealing temperature (times)   References
  -------------------------------- ----------------------------- ---------------------------- ----------------------------- ---------------- ------------------------------- -------------------------
  AMP                              *blaTEM*                      OT-1                         TTGGGTGCACGAGTGGGT            503 bp           58°C (1 min)                    \[[@b26-ophrp-11-216]\]
  OT-2                             TAATTGTTGCCGGGAAGC                                                                                                                        
  *blaOxa*                         OO-1                          ACCAGATTCAACTTTCAA           598 bp                        57°C (1 min)     \[[@b26-ophrp-11-216]\]         
  OO-2                             TCTTGGCTTTTATGCTTG                                                                                                                        
  *BlaPSE-1*                       PSE-1-F                       TTT GGT TCC GCG CTA TCT G    150                           51°C (1 min)     \[[@b27-ophrp-11-216]\]         
  PSE-1-R                          TAC TCC GAG CAC CAA ATC CG                                                                                                                
                                                                                                                                                                             
  CHL                              *cat1*                        CAT1-F                       TCCCAATGGCATCGTAAAGAAC        293 bp           53°C (30 s)                     \[[@b28-ophrp-11-216]\]
  CAT1-R                           TCGTGGTATTCACTCCAGAGCG                                                                                                                    
  *cat2*                           CAT2-F                        AACGGCATGATGAACCTGAA         547 bp                        55°C (30 s)      \[[@b29-ophrp-11-216]\]         
  CAT2-R                           ATCCCAATGGCATCGTAAAG                                                                                                                      
  *floR*                           floR-F                        ACTCGGCATGGACATGTACT         1213 bp                       55°C (40 s)      \[[@b29-ophrp-11-216]\]         
  floR-R                           ACGGACTGCGGAATCCATAG                                                                                                                      
  *cmIA*                           cmIA-F                        TGTCATTTACGGCATACTCG                                       55°C (30 s)      \[[@b26-ophrp-11-216]\]         
  cmIA-R                           ATCAGGCATCCCATTCCCAT                                                                                                                      
                                                                                                                                                                             
  TET                              *tetA*                        tetA-F                       GTAATTCTGAGCACTGTCGC          956 bp           58.5°C (1 min)                  \[[@b30-ophrp-11-216]\]
  tetA-R                           CTGCCTGGACAACATTGCTT                                                                                                                      
  *tetB*                           tetB-F                        CTCAGTATTCCAAGCCTTTG         415 bp                        55°C (45 s)      \[[@b30-ophrp-11-216]\]         
  tetB-R                           ACTCCCCTGAGCTTGAGGGG                                                                                                                      
  *tetG*                           tetG-F                        CAG CTT TCG GAT TCT TAC GG   884 bp                        60°C (45 s)      \[[@b31-ophrp-11-216]\]         
  tetG-R                           GAT TGG TGA GGC TCG TTA GC                                                                                                                
                                                                                                                                                                             
  SXT                              *dfrXII (dfrA12, dfrA13)*     dfrXII-F                     GGT GSG CAG AAG ATT TTT CGC   319 bp           60°C (45 s)                     \[[@b32-ophrp-11-216]\]
  dfrXII-R                         TGG GAA GAA GGC GTC ACC CTC                                                                                                               
  *dfrA7, dfrA17*                  dfrVII-F                      TTG AAA ATT TCA TTG ATT G    474 bp                        55°C (1 min)     \[[@b32-ophrp-11-216]\]         
  dfrVII-R                         TTA GCC TTT TTT CCA AAT CT                                                                                                                
  *dfrIa (dfrA1, dfrA5, dfrA15)*   dfrIa-F                       GTG AAA CTA TCA CTA ATG G    474 bp                        55°C (1 min)     \[[@b32-ophrp-11-216]\]         
  dfrIa-R                          TTA ACC CTT TTG CCA GAT TT                                                                                                                
  *sul1*                           sul1-F                        CGGCGTGGGCTACCTGAACG         432 bp                        60°C (30 s)      \[[@b33-ophrp-11-216]\]         
  sul1-R                           GCCGATCGCGTGAAGTTCCG                                                                                                                      
  *sul2*                           sul2-F                        TCA ACA TAA CCT CGG ACA GT   707 bp                        55°C (45 s)      \[[@b34-ophrp-11-216]\]         
  sul2-R                           GAT GAA GTC AGC TCC ACC T                                                                                                                 
  *sul3*                           sul3-F                        GGAAGAAATCAAAAGACTCAA        363 bp                        53°C (1 min)     \[[@b33-ophrp-11-216]\]         
  sul3-R                           CCTAAAAAGAAGCCCATACC                                                                                                                      
                                                                                                                                                                             
  DNA gyrase                       *gyrA*                        gyrA-F                       TGTCCGAGATGGCCTGAAGC          347 bp           62°C (45 s)                     \[[@b35-ophrp-11-216]\]
  gyrA-R                           TACCGTCATAAGTTATCCACG                                                                                                                     
  *gyrB*                           gyrB-F                        CAAACTGGCGGACTGTCAGG         345 bp                        62°C (45 s)      \[[@b35-ophrp-11-216]\]         
  gyrB-R                           TTCCGGCATCTGACGATAGA                                                                                                                      
  DNA topoisomerase                *parC*                        parC-F                       TGTATGCGATGTCTGAACTG          264 bp           55°C (30 s)                     \[[@b36-ophrp-11-216]\]
  parC-R                           CTCAATAGCAGCTCGGAATA                                                                                                                      

AMP = ampicillin; CHL = chloramphenicol; SXT = trimethoprim-sulphamethoxazole; TET = tetracycline.

###### 

Clinical attributes of individuals affected with enterovirulent *E. coli* (*n* = 119).

  Clinical Characteristics         Total DEC isolates (*n* = 119)   Enterovirulent *E. coli*, Frequency (%)                           
  -------------------------------- -------------------------------- ----------------------------------------- ------------ ---------- ----------
  Sex                                                                                                                                 
   Male                            56 (47.06)                       28 (23.53)                                19 (15.97)   2 (1.68)   7 (5.88)
   Female                          63 (52.94)                       28 (23,53)                                25 (21.01)   5 (4.20)   5 (4.20)
                                                                                                                                      
  Age groups (y)                                                                                                                      
   20--30                          32 (26.89)                       14 (11.76)                                14 (11.76)   0 (0.00)   4 (3.36)
   30--40                          22 (18.49)                       3 (2.52)                                  7 (5.88)     0 (0.00)   1 (0.84)
   40--50                          36 (30.25)                       22 (18.49)                                9 (7.56)     3 (2.52)   2 (1.68)
   50--60                          16 (13.45)                       6 (5.04)                                  5 (4.20)     2 (1.68)   3 (2.52)
   60--70                          19 (15.97)                       7 (5.88)                                  9 (7.56)     1 (0.84)   2 (1.68)
   ≥ 70                            5 (4.20)                         4 (3.36)                                  0 (0.00)     1 (0.84)   0 (0.00)
                                                                                                                                      
  Symptoms                                                                                                                            
   Abdominal cramps                24 (20.17)                       0 (0.00)                                  24 (20.17)   0 (0.00)   0 (0.00)
   Abdominal cramps and diarrhea   6 (5.04)                         0 (0.00)                                  6 (5.04)     0 (0.00)   0 (0.00)
   Abdominal pain                  2 (1.68)                         0 (0.00)                                  2 (1.68)     0 (0.00)   0 (0.00)
   Abdominal pain and vomiting     12 (10.08)                       0 (0.00)                                  12 (10.08)   0 (0.00)   0 (0.00)
   Dysenteric stools               5 (4.20)                         1 (0.84)                                  0 (0.00)     4 (3.36)   0 (0.00)
   Dysenteric stools and cramps    3 (2.52)                         0 (0.00)                                  0 (0.00)     3 (2.52)   0 (0.00)
   Fever and diarrhea              18 (15.13)                       18 (15.13)                                0 (0.00)     0 (0.00)   0 (0.00)
   Fever and vomiting              11 (9.24)                        11 (9.24)                                 0 (0.00)     0 (0.00)   0 (0.00)
   Stomach cramps and diarrhea     9 (7.56)                         0 (0.00)                                  0 (0.00)     0 (0.00)   9 (7.56)
   Stomach cramps and vomiting     3 (2.52)                         0 (0.00)                                  0 (0.00)     0 (0.00)   3 (2.52)
   Vomiting and diarrhea           26 (21.85)                       26 (21.85)                                0 (0.00)     0 (0.00)   0 (0.00)

EAEC = enteroaggregative *E. coli*; EIEC = enteroinvasive *E. coli*; EPEC = enteropathogenic *E. coli*; ETEC = enterotoxigenic *E. coli*.

###### 

Antimicrobial resistance profiles of isolated enterovirulent *E. coli* according to pathotype groups.

  Antibiotics     Enterovirulent *E. coli*   X^2^ (*p*)                                             
  --------------- -------------------------- ------------- ------------- ------------ ------------- ------------------
  AMP             S (*n* = 25)               3 (5.36)      18 (40.91)    3 (42.86)    1 (8.33)      21.94 (\< 0.001)
  I (*n* = 00)    0 (0.0)                    0 (0.0)       0 (0.0)       0 (0.0)                    
  R (*n* = 94)    53 (94.64)                 26 (59.09)    4 (57.14)     11 (91.67)                 
                                                                                                    
  AZM             S (*n* = 43)               24 (42.86)    16 (36.36)    1 (14.29)    2 (16.67)     10.41 (0.108)
  I (*n* = 73)    32 (57.14)                 26 (59.09)    5 (71.43)     10 (83.33)                 
  R (*n* = 3)     0 (0,00)                   2 (4.55)      1 (14.29)     0 (0.00)                   
                                                                                                    
  CAZ             S (*n* = 118)              56 (100.00)   44 (100.00)   7 (100.00)   11 (96.67)    8.99 (0.029)
  I (*n* = 1)     0 (0.00)                   0 (0.00)      0 (0.00)      1 (8.33)                   
  R (*n* = 00)    0 (0.00)                   0 (0.00)      0 (0.00)      0 (0.00)                   
                                                                                                    
  CHL             S (*n* = 104)              55 (98.21)    32 (72.73)    5 (71.43)    12 (100.00)   19.77 (0.003)
  I (*n* = 3)     1 (1.79)                   2 (4.55)      0 (0.00)      0 (0.00)                   
  R (*n* = 12)    0 (0.00)                   10 (22.73)    2 (28.58)     0 (0.00)                   
                                                                                                    
  CIP             S (*n* = 110)              51 (91.07)    42 (95.45)    6 (85.71)    11 (91.67)    17.32 (0.008)
  I (*n* = 8)     5 (8.93)                   2 (4.55)      0 (0.00)      1 (8.33)                   
  R (*n* = 1)     0 (0.00)                   0 (0.00)      1 (14.29)     0 (0.00)                   
                                                                                                    
  CRO             S (*n* = 115)              55 (98.21)    42 (95.45)    7 (100.00)   11 (91.67)    1.77 (0.620)
  I (*n* = 4)     1 (1.79)                   2 (4.55)      0 (0.00)      1 (8.33)                   
  R (*n* = 00)    0 (0.00)                   0 (0.00)      0 (0.00)      0 (0.00)                   
                                                                                                    
  CTX             S (*n* = 110)              52 (92.86)    40 (90.91)    7 (100.00)   11 (91.67)    0.7440 (0.862)
  I (*n* = 9)     4 (7.14)                   4 (9.09)      0 (0.00)      1 (8.33)                   
  R (*n* = 00)    0 (0.00)                   0 (0.00)      0 (0.00)      0 (0.00)                   
                                                                                                    
  GEN             S (*n* = 106)              56 (100.00)   32 (72.73)    7 (100.00)   12 (100.00)   22.4666 (0.001)
  I (*n* = 10)    0 (0.00)                   10 (22.73)    0 (0.00)      0 (0.00)                   
  R (*n* = 2)     0 (0.00)                   2 (4.55)      0 (0.00)      0 (0.00)                   
                                                                                                    
  MEM             S (*n* = 119)              56 (100.00)   44 (100.00)   7 (100.00)   12 (100.00)   0.00 (1.000)
  I (*n* = 00)    0 (0.00)                   0 (0.00)      0 (0.00)      0 (0.00)                   
  R (*n* = 00)    0 (0.00)                   0 (0.00)      0 (0.00)      0 (0.00)                   
                                                                                                    
  NA              S (*n* = 95)               49 (87.50)    30 (68.18)    5 (71.43)    11 (91.67)    7.1052 (0.068)
  I (*n* = 00)    0 (0.00)                   0 (0.00)      0 (0.00)      0 (0.00)                   
  R (*n* = 24)    7 (12.50)                  14 (3182)     2 (28.57)     1 (8.33)                   
                                                                                                    
  NOR             S (*n* = 118)              56 (100.00)   44 (100.00)   6 (85.71)    12 (100.00)   16.1356 (0.001)
  I (*n* = 00)    0 (0.00)                   0 (0.00)      0 (0.00)      0 (0.00)                   
  R (*n* = 1)     0 (0.00)                   0 (0.00)      1 (14.29)     0 (0.00)                   
                                                                                                    
  OFX             S (*n* = 118)              56 (100.00)   44 (100.00)   6 (85.71)    12 (100.00)   16.1356 (0.001)
  I (*n* = 00)    0 (0.00)                   0 (0.00)      0 (0.00)      0 (0.00)                   
  R (*n* = 1)     0 (0.00)                   0 (0.00)      1 (14.29)     0 (0.00)                   
                                                                                                    
  SXT             S (*n* = 12)               0 (0.00)      8 (18.18)     2 (28.57)    2 (16.67)     12.6746 (0.005)
  I (*n* = 00)    0 (0.00)                   0 (0.00)      0 (0.00)      0 (0.00)                   
  R (*n* = 107)   56 (100.00)                36 (81.82)    5 (71.43)     10 (83.33)                 
                                                                                                    
  TET             S (*n* = 13)               4 (7.14)      6 (13.64)     1 (14.29)    2 (16.67)     10.9165 (0.091)
  I (*n* = 5)     0 (0.00)                   5 (11.36)     0 (0.00)      0 (0.00)                   
  R (*n* = 101)   52 (92.86)                 33 (75.00)    6 (13.64)     10 (83.33)                 

AMP = ampicillin; CAZ = ceftazidime; CHL = chloramphenicol; CIP = ciprofloxacin; CRO = ceftriaxone; CTX = cefotaxime; EAEC = enteroaggregative *E. coli*; EIEC = enteroinvasive *E. coli*; EPEC = enteropathogenic *E. coli*; ETEC = enterotoxigenic *E. coli*; GEN = gentamicin; I = intermediate; MEM = meropenem; NA = nalidixic acid; NOR = norfloxacin; R = resistant; S = sensitive; SXT = trimethoprim-sulphamethoxazole; TET = tetracycline.

###### 

Percentage of *E. coli* antimicrobial resistant genes and their distribution according to pathotype groups.

  Antibiotics & resistant genes   Enterovirulent *E. coli*   X^2^ (*p*)                                                                     
  ------------------------------- -------------------------- ---------------- ------------- ------------- ------------ -------------------- --------------------
  AMP                             *BlaOxa*                   Yes (*n* = 11)   0 (0.00)      9 (20.45)     2 (28.57)    0 (0.00)             16.6348 (\< 0.001)
  No (*n* = 108)                  56 (100.00)                35 (79.55)       5 (71.43)     12 (100.00)                                     
  *BlaTEM*                        Yes (*n* = 62)             37 (66.07)       14 (31.82)    2 (28.57)     9 (75.00)    15.7073 (0.001)      
  No (*n* = 57)                   19 (33.93)                 30 (68.18)       5 (71.43)     3 (25.00)                                       
  *BlaPSE-1*                      Yes (*n* = 1)              0 (0.00)         1 (2.27)      0 (0.00)      0 (0.00)     1.7190 (0.632)       
  No (*n* = 118)                  56 (100.00)                43 (97.73)       7 (100.00)    12 (100.00)                                     
                                                                                                                                            
  CHL                             *cat1*                     Yes (*n* = 12)   0 (0.00)      10 (22.73)    2 (28.57)    0 (0.00)             18.0219 (\< 0.001)
  No (*n* = 107)                  56 (100.00)                34 (77.27)       125 (71.43)   12 (100.00)                                     
  *cat2*                          Yes (*n* = 12)             0 (0.00)         10 (22.73)    2 (28.57)     0 (0.00)     18.0219 (\< 0.001)   
  No (*n* = 107)                  56 (100.00)                34 (77.27)       125 (71.43)   12 (100.00)                                     
  *cmIA*                          Yes (*n* = 00)             0 (0.00)         0 (0.00)      0 (0.00)      0 (0.00)     0.0000 (1.000)       
  No (*n* = 119)                  56 (100.00)                44 (100.00)      7 (100.00)    12 (100.00)                                     
  *floR*                          Yes (*n* = 00)             0 (0.00)         0 (0.00)      0 (0.00)      0 (0.00)     0.0000 (1.000)       
  No (*n* = 119)                  56 (100.00)                44 (100.00)      7 (100.00)    12 (100.00)                                     
                                                                                                                                            
  TET                             *tetA*                     Yes (*n* = 63)   33 (58.93)    21 (47.73)    1 (14.29)    8 (66.67)            6.3917 (0.094)
  No (*n* = 56)                   23 (41.07)                 23 (52.27)       6 (85.71)     4 (33.33)                                       
  *tetB*                          Yes (*n* = 77)             35 (62.50)       31 (70.45)    0 (0.00)      11 (91.67)   17.4088 (0.006)      
  No (*n* = 42)                   21 (37.50)                 13 (29.55)       7 (100.00)    1 (8.33)                                        
  *tetG*                          Yes (*n* = 21)             5 (8.93)         7 (15.91)     6 (85.71)     3 (25.00)    25.7832 (\< 0.001)   
  No (*n* = 98)                   51 (91.07)                 37 (84.09)       1 (14.29)     9 (75.00)                                       
                                                                                                                                            
  SXT                             *dfr12*                    Yes (*n* = 1)    0 (0.00)      0 (0.00)      0 (0.00)     1 (8.33)             8.9922 (0.029)
  No (*n* = 118)                  56 (100.00)                44 (100.00)      7 (100.00)    11 (91.67)                                      
  *dfr7*                          Yes (*n* = 00)             0 (0.00)         0 (0.00)      0 (0.00)      0 (0.00)     0.0000 (1.000)       
  No (*n* = 119)                  56 (100.00)                44 (100.00)      7 (100.00)    12 (100.00)                                     
  *dfr1a*                         Yes (*n* = 8)              5 (8.93)         3 (6.82)      0 (0.00)      0 (0.00)     1.8046 (0.613)       
  No (*n* = 111)                  51 (91.07)                 41 (93.18)       7 (100.00)    12 (100.00)                                     
  *sul1*                          Yes (*n* = 20)             1 (1.79)         18 (40.91)    1 (14.29)     0 (0.00)     29.7739 (\< 0.001)   
  No (*n* = 99)                   55 (98.21)                 26 (59.09)       6 (85.71)     12 (100.00)                                     
  *sul2*                          Yes (*n* = 85)             46 (82.14)       23 (52.27)    5 (71.43)     11 (91.67)   13.4697 (0.003)      
  No (*n* = 34)                   10 (17.86)                 21 (47.73)       2 (28.57)     1 (8.33)                                        
  *sul3*                          Yes (*n* = 7)              3 (5.36)         2 (4.55)      2 (28.57)     0 (0.00)     7.4289 (0.059)       
  No (*n* = 112)                  53 (94.64)                 42 (95.45)       5 (71.43)     12 (100.00)                                     

AMP = ampicillin; CHL = chloramphenicol; EAEC = enteroaggregative *E. coli*; EIEC = enteroinvasive *E. coli*; EPEC = enteropathogenic *E. coli*; ETEC = enterotoxigenic *E. coli*; SXT = trimethoprim-sulphamethoxazole; TET = tetracycline.

###### 

Association between *E. coli* virulent genes and antimicrobial susceptibility phenotypes (*p* \< 0.05).

  Virulent genes (%)                                      Antibiotics (% resistance, % sensitive)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  
  ------------------------------------------------------- ----------------------------------------- ---------------------------------------------------- ------------------------------------------------------- ------------------------------------------------------- ------------- ------------- --------------------------------------------------------- -------------- ------------------------------------------------------- ------------------------------------------------------- ------------------------------------------------------- ------------------------------------------------------- ---------------------------------------------------- --------------
  *eae* (47.07)                                           56.38-12.00                               0.00-55.81                                           0.00-47.46                                              0.00-52.88                                              0.00-46.36    00.00-47.83   00-47.27                                                  0.00-52.83     0.00-47.06                                              29.17-51.58                                             0.00-47.46                                              0.00-47.46                                              52.34-0.00                                           51.49-30.77
  \< 0.001[\*](#tfn8-ophrp-11-216){ref-type="table-fn"}                                                                                                  0.002[\*\*](#tfn9-ophrp-11-216){ref-type="table-fn"}                                                                                        0.002[\*\*](#tfn9-ophrp-11-216){ref-type="table-fn"}                                                                                                                                                                                             \< 0.001[\*](#tfn8-ophrp-11-216){ref-type="table-fn"}   0.036[\*](#tfn8-ophrp-11-216){ref-type="table-fn"}   
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   
  *aaic* (13.45)                                          12.77-16.00                               00.00-6.98                                           00.00-13.56                                             83.33-4.81                                              0.00-14.55    0.00-13.04    0.00-12.73                                                0.00-6.60      0.00-13.45                                              45.83--5.26                                             0.00--13.56                                             0.00--13.56                                             14.02--8.33                                          10.89--23.03
                                                                                                                                                         \< 0.001[\*](#tfn8-ophrp-11-216){ref-type="table-fn"}                                                                                       \< 0.001[\*\*](#tfn9-ophrp-11-216){ref-type="table-fn"}                  \< 0.001[\*](#tfn8-ophrp-11-216){ref-type="table-fn"}                                                                                                                                                                                                                                
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   
  *CVD432* (33.61)                                        27.66-56.66                               66.67-34.88                                          0.00-33.90                                              83.33-27.88                                             0.00-34.55    0.00-33.04    0.00-32.73                                                100.00-26.42   0.00-33.61                                              58.33-27.37                                             0.00-33.90                                              0.00-33.90                                              30.84-58.33                                          32.67-23.08
  0.007[\*\*](#tfn9-ophrp-11-216){ref-type="table-fn"}                                                                                                   \< 0.001[\*](#tfn8-ophrp-11-216){ref-type="table-fn"}                                                                                       \< 0.001[\*](#tfn8-ophrp-11-216){ref-type="table-fn"}                    0.004[\*](#tfn8-ophrp-11-216){ref-type="table-fn"}                                                                                                                                                                                                                                   
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   
  *ial* (5.88)                                            4.26-12.00                                33.33-2.33                                           0.00-5.93                                               16.67-4.81                                              100.00-5.45   0.00-6.09     0.00-6.36                                                 0.00-6.60      0.00-5.88                                               8.33-5.26                                               100.00-5.08                                             100.00-5.08                                             4.67-16.67                                           5.94-7.69
                                                                                                                                                                                                                 \< 0.001[\*](#tfn8-ophrp-11-216){ref-type="table-fn"}                                                                                                                                                                \< 0.001[\*](#tfn8-ophrp-11-216){ref-type="table-fn"}   \< 0.001[\*](#tfn8-ophrp-11-216){ref-type="table-fn"}                                                                                                                
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   
  *stx1* (0.84)                                           1.06-0.00                                 0.00-0.00                                            0.00-0.85                                               0.00-0.96                                               0.00-0.91     0.00-0.87     0.00-0.91                                                 0.00-0.94      0.00-0.84                                               0.00-1.05                                               0.00-0.85                                               0.00-0.85                                               0.93-0.00                                            0.99-0.00
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   
  *Stx2* (10.08)                                          11.70-4.00                                0.00-4.65                                            100.00-9.32                                             0.00-11.54                                              0.00-10.00    00.00-9.57    0.00-10.00                                                0.00-10.38     0.00-10.08                                              4.17-11.58                                              0.00-10.17                                              0.00-10.17                                              9.35-16.67                                           9.90-15.38
                                                                                                    0.002[\*](#tfn8-ophrp-11-216){ref-type="table-fn"}                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             

AMP = ampicillin; CAZ = ceftazidime; CHL = chloramphenicol; CIP = ciprofloxacin; CRO = ceftriaxone; CTX = cefotaxime; GEN = gentamicin; MEM = meropenem; NA = nalidixic acid; NOR = norfloxacin; SXT = trimethoprim-sulphamethoxazole; TET = tetracycline.

(% resistance, % sensitive); % of virulent gene among resistant strains - % of virulent gene among sensitive strains.

Positive association.

Negative association.

###### 

Association between *E. coli* virulent genes and antimicrobial resistant genes.

  Virulence gene                                             *BlaOxa*                                                   *BlaTEM*                                              *BlaPSE-1*                                                 *cat1*                                                     *cat2*        *cmIA*       *floR*                                                  *tetA*                                                     *tetB*                                                   *tetG*                                                *dfr12*       *dfr7*       *dfr1a*                                                    *Sul1*                                                     *Sul2*                                                *Sul3*
  ---------------------------------------------------------- ---------------------------------------------------------- ----------------------------------------------------- ---------------------------------------------------------- ---------------------------------------------------------- ------------- ------------ ------------------------------------------------------- ---------------------------------------------------------- -------------------------------------------------------- ----------------------------------------------------- ------------- ------------ ---------------------------------------------------------- ---------------------------------------------------------- ----------------------------------------------------- --------------
  *eae*                                                      0.00-51.85                                                 59.69-33.33                                           0.00-47.46                                                 0.00-52.34                                                 0.00-52.34    0.00-47.06   0.00-47.06                                              52.38-41.07                                                45.45-50.00                                              23.81-52.04                                           0.00-47.46    0.00-47.06   62.50-45.95                                                5.00-55.56                                                 54.12-29.41                                           42.86-47.32
  0.001[\*\*](#tfn12-ophrp-11-216){ref-type="table-fn"}      0.004[\*](#tfn11-ophrp-11-216){ref-type="table-fn"}                                                              \< 0.001[\*\*](#tfn12-ophrp-11-216){ref-type="table-fn"}   \< 0.001[\*\*](#tfn12-ophrp-11-216){ref-type="table-fn"}                                                                                                                                                 0.018[\*\*](#tfn12-ophrp-11-216){ref-type="table-fn"}                                                                                     \< 0.001[\*\*](#tfn12-ophrp-11-216){ref-type="table-fn"}   0.014[\*](#tfn11-ophrp-11-216){ref-type="table-fn"}                                                              
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
  *aaic*                                                     72.73-7.41                                                 4.84-22.81                                            100.00-12.71                                               75.00-6.54                                                 83.33-5.61    0.00-13.45   0.00-13.45                                              4.76-23.21                                                 14.29-11.90                                              19.05-12.24                                           0.00-13.56    0.00-13.45   0.00-14.41                                                 55.00-5.05                                                 4.71-35.29                                            0.00-14.29
  \< 0.001[\*\*](#tfn12-ophrp-11-216){ref-type="table-fn"}   \< 0.001[\*\*](#tfn12-ophrp-11-216){ref-type="table-fn"}   0.010[\*](#tfn11-ophrp-11-216){ref-type="table-fn"}   \< 0.001[\*](#tfn11-ophrp-11-216){ref-type="table-fn"}     \< 0.001[\*](#tfn11-ophrp-11-216){ref-type="table-fn"}                                0.003[\*\*](#tfn12-ophrp-11-216){ref-type="table-fn"}                                                                                                                                                                                                        \< 0.001[\*](#tfn11-ophrp-11-216){ref-type="table-fn"}     \< 0.001[\*\*](#tfn12-ophrp-11-216){ref-type="table-fn"}                                                         
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
  *CVD432*                                                   81.82-28.70                                                22.58-45.61                                           0.00-33.90                                                 75.00-28.97                                                83.33-28.04   0.00-33.61   0.00-33.61                                              33.33-33.93                                                37.66-26.19                                              28.57-34.69                                           0.00-33.90    0.00-33.61   37.50-33.33                                                85.00-23.23                                                24.71-55.88                                           28.57-33.903
  \< 0.001[\*](#tfn11-ophrp-11-216){ref-type="table-fn"}     0.007[\*\*](#tfn12-ophrp-11-216){ref-type="table-fn"}                                                            0.001[\*](#tfn11-ophrp-11-216){ref-type="table-fn"}        \< 0.001[\*](#tfn11-ophrp-11-216){ref-type="table-fn"}                                                                                                                                                                                                                                                                                             \< 0.001[\*](#tfn11-ophrp-11-216){ref-type="table-fn"}     0.001[\*\*](#tfn12-ophrp-11-216){ref-type="table-fn"}                                                            
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
  *ial*                                                      18.18-4.63                                                 3.23-8.77                                             0.00-5.93                                                  16.67-4.67                                                 16.67-4.67    0.00-5.88    0.00-5.88                                               1.59-10.71                                                 0.00-16.67                                               28.57-1.02                                            0.00-5.93     0.00-5.88    0.00-6.31                                                  5.00-6.06                                                  5.88-5.88                                             28.57-4.46
                                                                                                                                                                                                                                                                                                                               0.034[\*\*](#tfn12-ophrp-11-216){ref-type="table-fn"}   \< 0.001[\*\*](#tfn12-ophrp-11-216){ref-type="table-fn"}   \< 0.001[\*](#tfn11-ophrp-11-216){ref-type="table-fn"}                                                                                                                                                                                                          0.008[\*](#tfn11-ophrp-11-216){ref-type="table-fn"}   
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
  *stx1*                                                     0.00-0.93                                                  0.00-1.75                                             0.00-0.85                                                  0.00-0.93                                                  0.00-0.93     0.00-0.84    0.00-0.84                                               1.59-0.00                                                  1.30-0.00                                                0.00-1.02                                             0.00-0.85     0.00-0.84    0.00-0.90                                                  0.00-1.01                                                  1.18-0.00                                             0.00-0.89
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
  *Stx2*                                                     0.00-11.11                                                 14.52-5.26                                            0.00-10.17                                                 0.00-11.21                                                 0.00-11.21    0.00-10.08   0.00-10.08                                              12.70-7.14                                                 14.29-2.38                                               14.29-9.18                                            100.00-9.32   0.00-10.08   0.00-10.81                                                 0.00-12.12                                                 12.94-2.94                                            0.00-10.71
                                                                                                                                                                                                                                                                                                                                                                                       0.039[\*](#tfn11-ophrp-11-216){ref-type="table-fn"}                                                                 0.002[\*](#tfn11-ophrp-11-216){ref-type="table-fn"}                                                                                                                                                                                                          

Chi-square association output of *E. coli* virulent genes and antimicrobial resistant genes.

Positive association.

Negative association.

Figure titles and legends
